Revolution Medicines, Inc.
Revolution Medicines, Inc. (NASDAQ: RVMD) is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The company's website is located at ir.revmed.com. Revolution Medicines possesses sophisticated structure-based drug discovery capabilities built upon deep chemical… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Revolution Medicines, Inc. does
In the company’s own words
Revolution Medicines, Inc. (NASDAQ: RVMD) is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The company's website is located at ir.revmed.com. Revolution Medicines possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology expertise and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites on cancer targets.
The company's core innovation engine centers on its proprietary tri-complex technology platform designed to inhibit RAS(ON), the active GTP-bound form of RAS proteins. This differentiated mechanism of action represents the first class of RAS inhibitors in clinical development to specifically target the activated form of oncogenic RAS, offering potential improvements over first-generation RAS(OFF) inhibitors that interact exclusively with the inactive form. Revolution Medicines' research and development pipeline comprises inhibitors designed as both monotherapy and in combination with other RAS(ON) inhibitors and therapeutic agents.
The company's lead program, daraxonrasib, is a RAS(ON) multi-selective inhibitor designed to inhibit multiple oncogenic RAS variants at the G12, G13, and Q61 hotspot positions. Additional clinical-stage candidates include zoldonrasib, a G12D-selective inhibitor; elironrasib, a G12C-selective inhibitor; and RMC-5127, a G12V-selective inhibitor. The company is also developing a new class of RAS(ON) inhibitors designed to overcome RAS-driven drug resistance.
Revolution Medicines is advancing multiple global randomized Phase 3 registrational studies across pancreatic ductal adenocarcinoma, non-small cell lung cancer, and colorectal cancer. The company has established clinical collaborations with major pharmaceutical companies including Bristol Myers Squibb, Amgen, Summit Therapeutics, and Tango Therapeutics to evaluate its RAS(ON) inhibitors in combination with complementary therapeutic agents. Revolution Medicines relies on contract development and manufacturing organizations for all manufacturing activities and intends to retain significant development and commercialization rights to its product candidates, with plans to commercialize initially in the United States followed by key international markets.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- REDWOOD CITY, CA
- Fiscal year end
- December
- CIK
- 1628171
- SIC
- 2836
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Revolution Medicines, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Revolution Medicines, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Revolution Medicines, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Revolution Medicines, Inc.’s bonds, as funds hold them
Funds report holding 1 issues of Revolution Medicines, Inc.’s debt, $137.63M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 0.50%, maturing 2033 to 2033.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Revolution Medicines, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Revolution Medicines, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Revolution Medicines, Inc.'s last four quarterly filings that the numbers alone won't show?”